HYF

Immunoprecise Antibodies (HYFT) Q2 2024 Earnings

HYFT·Reported July 29, 2024·Before market open

Immunoprecise Antibodies reported Q2 2024 revenue of $4.7M, beat analyst consensus of $4.7M by $4.5K. Diluted EPS came in at $-0.52, missed the $-0.10 consensus by $0.42.

Revenue
$4.7Mbeat by $4.5K
Consensus: $4.7M
Diluted EPS
$-0.52missed by $0.42
Consensus: $-0.10
SEC

SEC Filings

Earnings release8-K not filed yet
Quarterly report10-Q / 10-K not filed yet

Filings will appear here once submitted to SEC EDGAR.

Q2 2024 Earnings FAQ

Common questions about Immunoprecise Antibodies's Q2 2024 earnings report.

Immunoprecise Antibodies (HYFT) reported Q2 2024 earnings on July 29, 2024 before market open.

Immunoprecise Antibodies reported revenue of $4.7M and diluted EPS of $-0.52 for Q2 2024.

Revenue beat the consensus estimate of $4.7M by $4.5K. EPS missed the consensus estimate of $-0.10 by $0.42.